JP2024523885A5 - - Google Patents

Info

Publication number
JP2024523885A5
JP2024523885A5 JP2023577514A JP2023577514A JP2024523885A5 JP 2024523885 A5 JP2024523885 A5 JP 2024523885A5 JP 2023577514 A JP2023577514 A JP 2023577514A JP 2023577514 A JP2023577514 A JP 2023577514A JP 2024523885 A5 JP2024523885 A5 JP 2024523885A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
her3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/098929 external-priority patent/WO2022262772A1/en
Publication of JP2024523885A publication Critical patent/JP2024523885A/ja
Publication of JP2024523885A5 publication Critical patent/JP2024523885A5/ja
Pending legal-status Critical Current

Links

JP2023577514A 2021-06-15 2022-06-15 抗her3抗体、それを含有する抗体薬物複合体及びそれらの用途 Pending JP2024523885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021099998 2021-06-15
CNPCT/CN2021/099998 2021-06-15
PCT/CN2022/098929 WO2022262772A1 (en) 2021-06-15 2022-06-15 Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof

Publications (2)

Publication Number Publication Date
JP2024523885A JP2024523885A (ja) 2024-07-02
JP2024523885A5 true JP2024523885A5 (cg-RX-API-DMAC7.html) 2025-06-20

Family

ID=84526843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577514A Pending JP2024523885A (ja) 2021-06-15 2022-06-15 抗her3抗体、それを含有する抗体薬物複合体及びそれらの用途

Country Status (10)

Country Link
US (1) US20240293565A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355787A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523885A (cg-RX-API-DMAC7.html)
KR (1) KR20240021294A (cg-RX-API-DMAC7.html)
CN (1) CN117500832A (cg-RX-API-DMAC7.html)
AU (1) AU2022293634A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222478A1 (cg-RX-API-DMAC7.html)
IL (1) IL309337A (cg-RX-API-DMAC7.html)
MX (1) MX2023015072A (cg-RX-API-DMAC7.html)
WO (1) WO2022262772A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4470570A1 (en) * 2022-01-28 2024-12-04 Duality Biologics (Suzhou) Co., Ltd. Her3 antibody-drug conjugate and use thereof
WO2026145527A1 (zh) * 2024-12-30 2026-07-09 映恩生物制药(苏州)有限公司 抗her3抗体药物偶联物的用途和使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
AU2010284018C1 (en) * 2009-08-21 2015-10-15 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
ME02637B (me) * 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
CA2813796C (en) * 2010-10-18 2019-01-15 Mediapharma S.R.L. Erbb3 binding antibody
WO2013071058A1 (en) * 2011-11-09 2013-05-16 The Uab Research Foundation Her3 antibodies and uses thereof
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP3091033A1 (en) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
EP3176183A1 (en) * 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
US12667557B2 (en) * 2017-02-28 2026-06-30 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate

Similar Documents

Publication Publication Date Title
TWI851552B (zh) 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物
JP2023522229A5 (cg-RX-API-DMAC7.html)
US20230073692A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2022506072A5 (cg-RX-API-DMAC7.html)
CN107735093A (zh) Cd123抗体和其结合物
JP2020513791A5 (cg-RX-API-DMAC7.html)
US11851460B2 (en) PD1 binding agents
CN104936617A (zh) Cd33抗体及其在治疗癌症中的用途
JP2012522513A5 (cg-RX-API-DMAC7.html)
JP2017535246A5 (cg-RX-API-DMAC7.html)
JP2018524349A5 (cg-RX-API-DMAC7.html)
JP2017512765A5 (cg-RX-API-DMAC7.html)
JP2017518040A5 (cg-RX-API-DMAC7.html)
CA3092174A1 (en) Pd1 binding agents
WO2015094900A1 (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
JP2018538368A (ja) 抗5t4抗体および抗体−薬物コンジュゲート
JP2023509214A5 (cg-RX-API-DMAC7.html)
CN118076387A (zh) 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法
JP2025503214A (ja) Her3抗体-薬物結合体及びその使用
JP2023549316A5 (cg-RX-API-DMAC7.html)
CN110678753A (zh) 用于治疗肺癌的组合物和方法
JP2025513745A5 (cg-RX-API-DMAC7.html)
JP2023509215A5 (cg-RX-API-DMAC7.html)
JP2025130076A5 (cg-RX-API-DMAC7.html)
IL309337A (en) Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and uses thereof